Publications:  Dr Ivana Sestak

Sestak I, Filipits M, Buus R, Rudas M, Balic M, Knauer M, Kronenwett R, Fitzal F et al.(2020). Prognostic Value of EndoPredict in Women with Hormone Receptor Positive, HER2-Negative Invasive Lobular Breast Cancer. Clin Cancer Res

Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE, Loibl S, Bonanni B et al. (2020). 10-year results of the International Breast Cancer Intervention Study II (IBIS-II). BREAST CANCER RESEARCH AND TREATMENT. Conference: UKIBCS vol. 180, 527-527.

Hale MJ, Cuzick J, Sestak I (2020). A genome-wide association study of vaginal discharge during tamoxifen therapy for breast cancer prevention. BREAST CANCER RESEARCH AND TREATMENT. Conference: UKIBCS vol. 180, 570-571.

Richman J, Allen M, Snuggs N, Sestak I, Ring A, Dowsett M (2020). Clinical utility of the clinical treatment score at 5 years (CTS5) in a single tertiary cancer centre. BREAST CANCER RESEARCH AND TREATMENT. Conference: UKIBCS vol. 180, 556-557.

Buus R, Sestak I, Dowsett M, Kronenwett R, Ferree S, Schnabel CA, Baehner FL, Cuzick J (2020). Correlations between and molecular drivers of oncotype DX, prosigna, EndoPredict and breast cancer index: a TransATAC study. BREAST CANCER RESEARCH AND TREATMENT. Conference: UKIBCS vol. 180, 543-543.

Sestak I, Kronenwett R, Buus R, Cuzick J, Dowsett M (2020). Prognostic value of EndoPredict and oncotype recurrence score according to patients' age. BREAST CANCER RESEARCH AND TREATMENT. Conference: UKIBCS vol. 180, 580-580.

Sestak I, Crager M, Cuzick J, Dowsett M, Shak S, Tang G, Gray R, Sparano J (2020). Validation of the Clinical Treatment Score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study. BREAST CANCER RESEARCH AND TREATMENT. Conference: UKIBCS vol. 180, 532-533.

Buus R, Sestak I, Dowsett M, Kronenwett R, Ferree S, Schnabel C, Baehner FL, Cuzick J (2020). Correlation between and molecular drivers of oncotype DX, prosigna, EndoPredict and breast cancer index: A TransATAC study. CANCER RESEARCH. Conference: SABCS vol. 80,

Sestak I, Ferree S, Shemesh I, Buckingham W, Cuzick J, Dowsett M (2020). Discordant classification and outcomes between Prosigna and Oncotype Dx Recurrence Score for ER-positive, HER2-negative, node-negative breast cancer. CANCER RESEARCH. Conference: SABCS vol. 80,

Van Cauwenberge J, Sestak I, Punie K, Wildiers H, Floris G, Vergote I, Berteloot P, Van Gorp T et al. (2020). Predicting distant recurrence of ER+HER2-breast cancer after 5 years of endocrine therapy: The CTS5-tool validation in real life. CANCER RESEARCH. Conference: SABCS vol. 80,

Sestak I, Kronenwett R, Buus R, Cuzick J, Dowsett M (2020). Prognostic value of EndoPredict and Oncotype Recurrence Score according to patient's age. CANCER RESEARCH. Conference: SABCS vol. 80,

Cuzick J, Sestak I, Forbes J, Dowsett M, Cawthorn S, Mansell R, Loibl S, Bonanni B et al. (2020). Ten year results of the international breast cancer intervention study II. CANCER RESEARCH. Conference: SABCS vol. 80,

Buus R, Sestak I, Barron S, Loughman T, Fender B, Ruiz CL, Dynoodt P, Wang CJA et al.(2020). Validation of the OncoMASTR risk score in estrogen receptor–positive/HER2-negative patients: A TransATAC study. Clinical Cancer Research vol. 26, (3) 623-631.

Sestak I, Crager M, Cuzick J, Dowsett M, Shak S, Tang G, Gray R, Sparano J (2020). Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study. CANCER RESEARCH. Conference: SABCS vol. 80,

Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE, Loibl S, Bonanni B et al.(2020). Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet vol. 395, (10218) 117-122.

Sestak I, Blake GM, Patel R, Coleman RE, Cuzick J, Eastell R(2019). Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. Bone vol. 124, 83-88.

Sestak I, Zhang Y, Schnabel CA, Cuzick JM, Dowsett M (2019). Breast Cancer Index and risk stratification in luminal subtypes: A trans-ATAC study. JOURNAL OF CLINICAL ONCOLOGY. Conference: ASCO vol. 37,

Richman J, Ring AE, Dowsett M, Sestak I (2019). Clinical validity of CTS5 for estimating risk of late recurrence in unselected, non-trial patients with early ER plus breast cancer. JOURNAL OF CLINICAL ONCOLOGY. Conference: ASCO vol. 37,

Sestak I, Filipits M, Buus R, Rudas M, Knauer M, Kronenwett R, Cuzick J, Gnant MI et al. (2019). Prognostic value of endopredict for invasive lobular carcinomas in the combined ABCSG-6/8 and TransATAC trials. ANNALS OF ONCOLOGY. Conference: ESMO Breast vol. 30,

SESTAK IVANA, CUZICK J(2019). Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Research and Treatment

Sestak I (2019). Clinical utility of prognostic assays for assessment of late recurrence. BREAST. Conference: St. Gallen Oncology conference vol. 44, S3-S3.

Dodson A, Sestak I, Bayani J, Dowsett M, Bartlett J, Cuzick J (2019). A newly derived combined clinical treatment score and immunohistochemical-4 prognostic tool. CANCER RESEARCH. Conference: SABCS vol. 79,

Sestak I, Dowsett M, Cuzick J (2019). Importance of adverse events during endocrine treatment for the prediction of late distant recurrences. CANCER RESEARCH. Conference: SABCS vol. 79,

Sestak I, Martin M, Dubsky P, Rojo F, Cuzick J, Filipits M, Ruiz A, Buus R et al. (2019). Prediction of distant recurrence by EndoPredict in patients with estrogen receptor-positive, HER2-negative breast cancer who received adjuvant endocrine therapy plus chemotherapy (ET plus C) or endocrine therapy alone (ET). CANCER RESEARCH. Conference: SABCS vol. 79,

Sestak I, Cuzick J (2018). Off-Treatment Bone Mineral Density Changes in Postmenopausal Women after 5 Years of Anastrozole. JOURNAL OF BONE AND MINERAL RESEARCH. Conference: ASBMR vol. 33, 102-103.

Sestak I, Cuzick J, Blake G, Patel R, Coleman R, Eastell R (2018). Off-treatment Bone Mineral Density Changes in Postmenopausal Women after 5 Years of Anastrozole. JOURNAL OF BONE AND MINERAL RESEARCH. Conference: ASBMR vol. 33, 46-46.

Sestak I(2018). Risk stratification in early breast cancer in premenopausal and postmenopausal women: integrating genomic assays with clinicopathological features. Curr Opin Oncol vol. 31, 29-34.

Buus R, Yeo B, Brentnall AR, Klintman M, Cheang MCU, Khabra K, Sestak I, Gao Q et al.(2018). Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer. Breast Cancer Research vol. 20, (1)

Macis D, Sestak I, Aristarco V, Johansson H, Guerrieri-Gonzaga A, Decensi A, Bonanni B, Cuzick J et al. (2018). Adiponectin, leptin and breast cancer in high risk postmenopausal women: Results from a nested case-control study. CANCER RESEARCH. Conference: AACR vol. 78,

Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J(2018). Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J Clin Oncol vol. 36, (19) 1941-1948.

Sestak I, Buus R, Cuzick JM, Barron S, Loughman T, Fender B, Ruiz CL, Dynoodt P et al. (2018). Evaluation of the OncoMasTR prognostic signature in postmenopausal women with primary ER-positive breast cancer. JOURNAL OF CLINICAL ONCOLOGY. Conference: ASCO vol. 36,

Smith SG, Sestak I, Morris MA, Howell A, Forbes JF, Cuzick JM (2018). Overweight and breast cancer risk in the International Breast Cancer Intervention studies I and II. JOURNAL OF CLINICAL ONCOLOGY. Conference: ASCO vol. 36,

Sestak I, Zhang Y, Sgroi D, Schnabel CA, Cuzick JM, Dowsett M (2018). Residual risk assessment with the Breast Cancer Index (BCI) for prediction of late distant recurrence (DR) in patients from the TransATAC study. JOURNAL OF CLINICAL ONCOLOGY. Conference: ASCO vol. 36,

SESTAK I, Buus R, CUZICK JM, Dubsky P, Kronenwett R, Denkert C, Ferree S, Sgroi D et al.(2018). Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer. JAMA Oncology

Sestak I, Regan M, Dodson A, Viale G, Thurlimann B, Colleoni M, Cuzick J, Dowsett M (2018). Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy. CANCER RESEARCH. Conference: SABCS vol. 78,

Sestak I, Smith S, Sleeth M, Howell A, Cuzick J (2018). Participant-reported symptoms as predictors of long-term adherence of endocrine therapy in the International breast cancer intervention studies 2 (IBIS-2). CANCER RESEARCH. Conference: SABCS vol. 78,

Sestak I, Kronenwett R, Denkert C, Cuzick J, Dowsett M (2018). Prognostic performance of EndoPredict in invasive lobular carcinoma. CANCER RESEARCH. Conference: SABCS vol. 78,

Sestak I, Smith SG, Howell A, Forbes JF, Cuzick J(2017). Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II. Ann Oncol

Heindl A, Sestak I, Naidoo K, Cuzick J, Dowsett M, Yuan Y(2017). Relevance of spatial heterogeneity of immune infiltration for predicting risk of recurrence after. JNCI: Journal of the National Cancer Institute

Smith SG, Sestak I, Howell A, Forbes J, Cuzick J(2017). Participant-reported symptoms and their impact on long-term adherence in the International Breast Cancer Intervention Study (IBIS-1). Journal of Clinical Oncology vol. 35, (23)

Sestak I(2017). Identifying Biomarkers to Select Patients with Early Breast Cancer Suitable for Extended Adjuvant Endocrine Therapy. BREAST CARE vol. 12, (3) 146-151.

CUZICK JM, Bartlett J, Ikhlaaq A, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thürlimannh B et al.(2017). HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. European Journal of Cancer

Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Ferree S, Sgroi D, Schnabel C et al. (2017). Comprehensive comparison of prognostic signatures for breast cancer in TransATAC. CANCER RESEARCH. Conference: San Antonio Breast Cancer Symposium vol. 77,

Cuzick J, Sestak I, Bianco A, Strobbe L, Bergh J, Hanusch C, Neven P, Dowsett M et al. (2017). Long-term comparison of anastrozole versus tamoxifen: Results from LATTE/ATAC. vol. 77, Abstract: java.sql.Clob org.hibernate.engine.jdbc.WrappedClob java.io.Serializable ,

Smith SG, Sestak I, Forbes J, Howell A, Cuzick JJ (2017). Menopausal symptoms as predictors of long-term adherence in the International breast cancer intervention study (IBIS-1). CANCER RESEARCH. Conference: San Antonio Breast Cancer Symposium vol. 77,

Heindl A, Sestak I, Naidoo K, Cuzick J, Dowsett M, Yuan Y(2017). Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence after Endocrine Therapy of ER+ Breast Cancer. Journal of the National Cancer Institute vol. 110, (2)

CUZICK J, BRENTNALL AR, Segal C, Byers H, Reuter C, Detre S, Lopez-Knowles E, Sestak I et al.(2016). Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. Journal of Clinical Oncology vol. 35, (7) 743-750.

Lakhanpal R, Sestak I, Shadbolt B, Bennett GM, Brown M, Phillips T, Zhang Y, Bullman A et al.(2016). IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer. The Breast vol. 29, Article C, 147-152.

Brentnall AR, Cuzick J, Byers H, Segal C, Reuter C, Detre S, Sestak I, Howell A et al.(2016). Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials. Breast Cancer Research and Treatment vol. 158, (3) 591-596.

Šestak I, Cuzick J(2016). Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors. Expert Rev Endocrinol Metab vol. 11, (5) 425-432.

Sestak I, Dowsett M, Ferree S, Baehner FL, Cuzick J(2016). Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors. Breast Cancer Research and Treatment vol. 159, (1)

Guerrieri-Gonzaga A, Sestak I, Lazzeroni M, Serrano D, Rotmensz N, Cazzaniga M, Varricchio C, Pruneri G et al.(2016). Benefit of low dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS. International Journal of Cancer vol. 139, (9) 2127-2134.

Guerrieri-Gonzaga A, Sestak I, Lazzeroni M, Serrano D, Rotmensz N, Cazzaniga M, Varricchio C, Thorat MA et al. (2016). Benefit of low-dose tamoxifen in a large, single-institution cohort of high-risk ER-positive DCIS. CANCER RESEARCH. Conference: AACR Annual Meeting vol. 76,

Sestak I, Zhang Y, Schroeder BE, Schnabel CA, Dowsett M, Cuzick J, Sgroi D(2016). Cross Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in women with hormone receptor positive lymph-node negative early stage breast cancer. Clinical Cancer Research vol. 22, (18)

Sestak I, Yeo B, Dodson A, Dowsett M, Cuzick JM (2016). Improved use of clinical variables for prognosis of distant recurrence in patients with ER plus breast cancer treated with 5 years endocrine therapy. JOURNAL OF CLINICAL ONCOLOGY. Conference: ASCO vol. 34,

Buus R, Sestak I, Kronenwett R, Denkert C, Dubsky P, Krappmann K, Scheer M, Petry C et al.(2016). Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. Journal of the National Cancer Institute vol. 108, (11)

Smith SG, Sestak I, Forster A, Partridge A, Side L, Wolf MS, Horne R, Wardle J et al.(2016). Factors affecting uptake and adherence to breast cancer chemoprevention: A systematic review and meta-analysis. Annals of Oncology vol. 27, (4) 575-590.

Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W et al.(2016). Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet vol. 387, (10021) 866-873.

Cuzick J, Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G et al. (2016). Anastrozole versus tamoxifen for the prevention of loco-regional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ (IBIS-II DCIS). CANCER RESEARCH. vol. 76,

Dowsett M, Sestak I, Buus R, Kronenwett R, Denkert C, Krappmann K, Scheer M, Petry C et al. (2016). EndoPredict (EPclin) score for estimating residual distant recurrence (DR) risk in ER+/HER2-breast cancer (br ca) patients treated with 5 years adjuvant endocrine therapy alone: Validation and comparison with the oncotype DX recurrence score (RS). CANCER RESEARCH. vol. 76,

Smith SG, Sestak I, Forster A, Partridge A, Side L, Horne R, Wardle J, Cuzick J (2016). Factors affecting uptake and adherence to breast cancer chemoprevention: A systematic review and meta-analysis. CANCER RESEARCH. vol. 76,

Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thurlimann BJK, Seynaeve C et al. (2016). HER2 status as predictive marker for Al vs Tam benefit: A TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. CANCER RESEARCH. vol. 76,

Sestak I, Zhang Y, Schroeder B, Dowsett M, Sgroi D, Cuzick J, Schnabel CA (2016). Integration of tumor size and grade with the breast cancer index (BCI) for prediction of distant recurrence in hormone receptor-positive breast cancer with 1-3 positive lymph nodes. CANCER RESEARCH. vol. 76,

Sestak I, Zhang Y, Schroeder B, Dowsett M, Sgroi D, Cuzick J, Schnabel CA (2016). Integration of tumor size and grade with the breast cancer index (BCl) for prediction of distant recurrence in hormone receptor-positive breast cancer with 1-3 positive lymph nodes. CANCER RESEARCH. vol. 76,

Zhang Y, Sestak I, Schroeder BE, Dowsett M, Cuzick J, Schnabel CA, Sgroi DC (2016). Prognostic impact of the combined risk groups by breast cancer index and HOXB13/IL17BR ratio in hormonal receptor positive, node negative breast cancer: A TransATAC study. CANCER RESEARCH. vol. 76,

Spagnolo F, Sestak I, Howell A, Forbes JF, Cuzick J(2015). Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. Journal of Clinical Oncology vol. 34, (2) 139-143.

Cuzick J, Sestak I, Thorat MA(2015). Impact of preventive therapy on the risk of breast cancer among women with benign breast disease. Breast vol. 24, S51-S55.

Bradley R, Burrett J, Clarke M, Davies C, Duane F, Evans V, Gettins L, Godwin J et al.(2015). Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. The Lancet vol. 386, (10001) 1341-1352.

Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, Liu S, Leung S et al.(2015). Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Medical Genomics vol. 8, (1)

Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E, Greil R, Dubsky P et al.(2015). Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Ann Oncol vol. 26, (8) 1685-1691.

Dowsett M, Sestak I, Buus R, Lopez-Knowles E, Mallon E, Howell A, Forbes JF, Buzdar A et al.(2015). Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. Clin Cancer Res vol. 21, (12) 2763-2770.

Mote PA, Gompel A, Howe C, Hilton HN, Sestak I, Cuzick J, Dowsett M, Hugol D et al.(2015). Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial. Breast Cancer Res Treat vol. 151, (2) 309-318.

Zhang Y, Sestak I, Cuzick JM, Dowsett M, Schnabel CA, Sgroi D (2015). Correlation of Breast Cancer Index HOXB13/IL17BR (H/I), ER, PR and HER2 and prediction of relative endocrine benefit from tamoxifen and anastrozole in HR plus breast cancer: A TransATAC study. JOURNAL OF CLINICAL ONCOLOGY. vol. 33,

Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF (2015). 16 year long-term follow-up of the IBIS-I breast cancer prevention trial. CANCER RESEARCH. vol. 75,

Sestak I, Zhang Y, Schroeder BE, Goss PE, Dowsett M, Sgroi DC, Schnabel CA, Cuzick J (2015). Integration of breast cancer index (BCI) with clinicopathological factors for prediction of distant recurrence in ER plus breast cancer. CANCER RESEARCH. vol. 75,

Hiscox S, Smith C, Nicholson RI, Gee J, Harris A, Bliss J, Kalaizak E, Sestak I et al. (2015). Nuclear beta-catenin negativity predicts for late relapse in ER plus , tamoxifen-treated breast cancer. CANCER RESEARCH. vol. 75,

Sestak I, Howell A, Forbes JF, Neven P, Cuzick J (2015). Timing, severity and risk factors for arthralgia in the IBIS-II trial: A retrospective and exploratory analysis. CANCER RESEARCH. vol. 75,

Sestak I, Cuzick J(2015). Update on breast cancer risk prediction and prevention. Curr Opin Obstet Gynecol vol. 27, (1) 92-97.

Sestak I, Cuzick J(2015). Markers for the identification of late breast cancer recurrence. Breast Cancer Res vol. 17,

Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF, IBIS-I Investigators(2015). Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol vol. 16, (1) 67-75.

Sestak I, Singh S, Cuzick J(2014). Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, doubleblind, randomised, placebo-controlled trial (vol 15, pg 1464, 2014). LANCET ONCOLOGY vol. 15, (13) E587-E587.

Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, Coleman R, Dowsett M et al.(2014). Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncology vol. 15, (13) 1460-1468.

Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P, Cowens JW, Ferree S et al.(2014). Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. Journal of Clinical Oncology vol. 33, (8) 916-922.

Sestak I, Zhang Y, Schnabel CA, Schroeder B, Ander ME, Goss PE, Cuzick JM, Dowsett M et al. (2014). Clinical impact of differential risk stratification by breast cancer index (BCI) versus recurrence score (RS) in HR plus early-stage breast cancer: A TransATAC study. JOURNAL OF CLINICAL ONCOLOGY. vol. 32,

Cuzick JM, Brentnall A, Segal C, Sestak I, Kealy R, Howell A, Powles TJ, Orr N et al. (2014). Use of a SNP panel to refine risk estimates in women at high risk of breast cancer: Results from two randomized tamoxifen prevention trials. JOURNAL OF CLINICAL ONCOLOGY. vol. 32,

Eastell R, Sestak I, Gossiel F, Patel R, Blake G, Coleman R, Howell A, Dowsett M et al. (2014). EFFECT OF AROMATASE INHIBITION ON BONE DENSITY AND BONE TURNOVER IN HEALTHY POSTMENOPAUSAL WOMEN: RESULTS OF THE INTERNATIONAL BREAST CANCER INTERVENTION STUDY II (IBIS-II). OSTEOPOROSIS INTERNATIONAL. vol. 25, S281-S281.

Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N et al.(2014). Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet vol. 383, (9922) 1041-1048.

Dowsett M, Sestak I, Buus R, Lopez-Knowles E, Cuzick J (2014). Oestrogen module of 21-gene recurrence score predicts increased late recurrence for ER+HER2-breast cancer. EUROPEAN JOURNAL OF CANCER. vol. 50, S105-S106.

Sestak I, Singh S, Cuzick J, Blake G, Patel R, Coleman R, Dowsett M, Forbes JF et al. (2014). Risedronate Prevents Anastrozole-Induced Bone Loss In The IBIS-II Prevention Trial. JOURNAL OF BONE AND MINERAL RESEARCH. vol. 29, S110-S110.

Sestak I(2014). Preventative therapies for healthy women at high risk of breast cancer. Cancer Manag Res vol. 6, 423-430.

Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N et al. (2013). Breast cancer prevention using anastrozole in postmenopausal women at high risk. CANCER RESEARCH. vol. 73,

Sestak I, Cuzick J, Dowsett M, Filipits M, Dubsky P, Cowens W, Ferree S, Schaper C et al.(2013). Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of 2485 patients from the ABCSG-8 and transATAC studies using the PAM50 risk of recurrence (ROR) score. CANCER RESEARCH vol. 73,

Allen MD, Thomas GJ, Clark S, Dawoud MM, Vallath S, Payne SJ, Gomm JJ, Dreger SA et al.(2013). Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of αvβ6 integrin in DCIS identifies high-risk patients and predicts recurrence. Clin Cancer Res vol. 20, (2) 344-357.

Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, Cuzick J(2013). Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst vol. 105, (19) 1504-1511.

Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A et al.(2013). Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol vol. 14, (11) 1067-1076.

Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, Ferree S, Storhoff J et al.(2013). Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol vol. 31, (22) 2783-2790.

Afentakis M, Dowsett M, Sestak I, Salter J, Howell T, Buzdar A, Forbes J, Cuzick J(2013). Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study. Breast Cancer Res Treat vol. 140, (2) 253-262.

Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF et al.(2013). Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet vol. 381, (9880) 1827-1834.

Pugliano L, Zardavas D, Paesmans M, Sestak I, Gelber RD, Cuzick JM, Dowsett M, Awada A et al. (2013). A meta-analysis of endocrine therapy trials in early breast cancer (BC) evaluating the impact of obesity: Are aromatase inhibitors (AIs) optimal therapy in obese ER plus BC?. JOURNAL OF CLINICAL ONCOLOGY. vol. 31,

Gnant M, Dowsett M, Filipits M, Lopez-Knowles E, Greil R, Balic M, Cowens JW, Nielsen TO et al. (2013). Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR plus early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype. JOURNAL OF CLINICAL ONCOLOGY. vol. 31,

Cummins NM, Jakeman PM, Sestak I, Murphy N, Carroll P(2013). The effect of behavioural risk factors on osteoporosis in Irish women. IRISH JOURNAL OF MEDICAL SCIENCE vol. 182, (1) 97-105.

Eastell R, Sestak I, Gossiel F, Patel R, Blake G, Coleman R, Howell A, Dowsett M et al. (2013). Effect of Aromatase Inhibition on Bone Density and Bone Turnover in Healthy Postmenopausal Women: Results of the International Breast cancer Intervention Study II (IBIS-II). JOURNAL OF BONE AND MINERAL RESEARCH. vol. 28,

Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Erlander MG, Goss PE, Dowsett M(2012). Comparative Performance of Breast Cancer Index (BCI) vs. Oncotype Dx and IHC4 in the Prediction of Late Recurrence in Hormonal Receptor-Positive Lymph Node-Negative Breast Cancer Patients: A TransATAC Study. CANCER RESEARCH vol. 72,

Sgroi DC, Sestak I, Zhang Y, Erlander MG, Schnabel CA, Goss PE, Cuzick J, Dowsett M(2012). Evaluation of Prognostic and Predictive Performance of Breast Cancer Index and Its Components in Hormonal Receptor-Positive Breast Cancer Patients: A TransATAC Study. CANCER RESEARCH vol. 72,

Sestak I, Cuzick J(2012). Preventive therapy for breast cancer. Curr Oncol Rep vol. 14, (6) 568-573.

Rae JM, Hayes DF, Cuzick J, Sestak I, Dowsett M(2012). CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients (vol 104, pg 452, 2012). JOURNAL OF THE NATIONAL CANCER INSTITUTE vol. 104, (22) 1772-1772.

Cuzick J, Sestak I, Ferree S, Cowens JW, Dowsett M (2012). PREDICTION OF LATE BREAST CANCER RECURRENCE BY THE ROR (PAM50) SCORE IN POSTMENOPAUSAL WOMEN IN THE TRANSATAC COHORT. ANNALS OF ONCOLOGY. vol. 23, 75-76.

Zgorelec Z, Pehnec G, Baši¿ F, Kisi¿ I, Mesi¿ M, Zužul S, Juriši¿ A, Sestak I et al.(2012). Sulphur cycling between terrestrial agroecosystem and atmosphere. Arh Hig Rada Toksikol vol. 63, (3) 301-310.

Jurisic A, Mesic M, Zgorelec Z, Sestak I (2012). Micro-analysis of soil total and mineral nitrogen under different nitrogen fertilization levels. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. vol. 244,

Dixon JM, Sestak I, Cuzick J(2012). ABC of Breast Diseases. BMJ Books

Rae JM, Hayes DF, Cuzick J, Sestak I, Dowsett M(2012). Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial Response. JOURNAL OF THE NATIONAL CANCER INSTITUTE vol. 104, (16) 1267-1268.

Sestak I, Kealy R, Nikoloff M, Fontecha M, Forbes JF, Howell A, Cuzick J(2012). Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial. Br J Cancer vol. 107, (2) 230-233.

Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick J(2012). Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. Breast Cancer Res Treat vol. 134, (2) 727-734.

Iqbal J, Ginsburg OM, Wijeratne TD, Howell A, Evans G, Sestak I, Narod SA(2012). Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review. CANCER TREATMENT REVIEWS vol. 38, (4) 318-328.

Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I et al.(2012). CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst vol. 104, (6) 452-460.

Pinhel I, Hills M, Drury S, Salter J, Sumo G, A'Hern R, Bliss JM, Sestak I et al.(2012). ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Res vol. 14, (2)

Rae JM, Sestak I, Henry NL, Drury S, Hayes DF, Thibert JN, Lopez-Knowles E, Salter J et al.(2011). Correlation between Gene Variants in CYP19 (Aromatase) and TCL1A with Disease and Tolerability Endpoints in the ATAC Trial. CANCER RESEARCH vol. 71,

Sestak I, Cuzick J, Dowsett M, Salter J, Quinn E, Zabaglo L, Howell A, Buzdar A et al.(2011). Prediction of Residual Risk of Recurrence after 5 Years of Follow-Up by Clinicopathologic Variables and 4 IHC Markers: A TransATAC Study. CANCER RESEARCH vol. 71,

Ring A, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, Forbes JF, Cuzick J(2011). Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. J Clin Oncol vol. 29, (32) 4266-4272.

Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick JM(2011). Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with breast cancer or at high risk of developing it. JOURNAL OF CLINICAL ONCOLOGY vol. 29, (27)

Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick JM(2011). Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with breast cancer or at high risk of developing it. J Clin Oncol vol. 29, (27_suppl)

Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, for the ATAC/LATTE investigators(2011). 10-year analysis of the ATAC trial: wrong conclusion? - Authors' reply. Lancet Oncol vol. 12, (3)

Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC LATTE Investigators(2011). 10-year analysis of the ATAC trial: wrong conclusion? Reply. LANCET ONCOL vol. 12, (3) 217-217.

Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H et al.(2011). Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol vol. 12, (1) 21-29.

Ring AE, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, Forbes JF, Cuzick J (2010). The Influences of Co-Morbidities and Age on Risk of Death without Recurrence: A Retrospective Analysis of the ATAC Trial. CANCER RESEARCH. vol. 70,

Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC LATTE Investigators(2010). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. LANCET ONCOL vol. 11, (12) 1135-1141.

Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC/LATTE investigators(2010). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol vol. 11, (12) 1135-1141.

Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J(2010). Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol vol. 28, (21) 3411-3415.

Cuzick J, Sestak I, Pinder SE, Ellis IO, Hackshaw A, Bundred NJ, Forbes JF, Bishop H et al. (2009). Beneficial Effect of Tamoxifen for Women with DCIS: Long-Term Results front the UK/ANZ DCIS Trial in Women with Locally Excised DCIS. CANCER RESEARCH. vol. 69, 493S-493S.

Sestak I, Distler W, Forbes JF, Howell A, Cuzick J (2009). Effect of Body Mass Index on Recurrence in Hormone Receptor Positive Early Breast Cancer - A Retrospective Exploratory Analysis from the ATAC Trial. CANCER RESEARCH. vol. 69, 553S-553S.

Sestak I, Sapunar F, Cuzick J(2009). Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol vol. 27, (30) 4961-4965.

Sestak I, Cuzick J (2009). Characteristics of carpal-tunnel syndrome in the ATAC trial. CANCER RESEARCH. vol. 69, 326S-326S.

Cuzick J, Sestak I, Cella D, Fallowfield L, ATAC Trialists' Group(2008). Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol vol. 9, (12) 1143-1148.

Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU, ATAC Trialists' Group(2008). Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol vol. 9, (9) 866-872.

SESTAK I (2008). Breast Cancer Chemoprevention: A Risk-benefit Profile for Tamoxifen and Anastrozole. Supervisors: Cuzick, J,

Sestak I, Forbes JF, Edwards R, Howell A, Cuzick J (2008). Timing and severity of prominent side effects of anastrozole and tamoxifen. EJC SUPPLEMENTS. vol. 6, 71-71.

Sestak I, ATAC Trialists Grp (2007). Risk factors for joint symptoms in the ATAC trial. BREAST CANCER RESEARCH AND TREATMENT. vol. 106, S108-S108.

Sestak I, Edwards R, Howell A, Cuzick J (2007). Effect of tamoxifen on serum lipid levels in women at increased risk of breast cancer. EJC SUPPLEMENTS. vol. 5, 31-31.

Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, International Breast Cancer Intervention Study I Investigators(2007). Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst vol. 99, (4) 272-282.

Sestk I, Edwards R, Howell A, Cuzick J (2007). Comparison of side-effect profiles during active treatment versus follow-up in the International Breast Cancer Intervention Study I tamoxifen prevention trial. BREAST CANCER RESEARCH. vol. 9,

Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J (2006). Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol. vol. 24, 3991-3996.

Sestak I, Forbes J, Roseann K, Edwards R, Howell A, Cuzick J (2006). Comparison of side-effect profiles during active treatment versus follow-up in the IBIS-1 tamoxifen prevention study. BREAST CANCER RESEARCH AND TREATMENT. vol. 100, S55-S55.

Sestak I, Kealy R, Edwards R, Cuzick J (2005). The influence of hormone replacement therapy (HRT) on tamoxifen induced vasomotor symptoms. BREAST CANCER RESEARCH AND TREATMENT. vol. 94, S11-S12.